Skip to main content

Advertisement

SpringerLink
Log in

Increased serum concentrations of soluble tumor necrosis factor receptor I in noncachectic and cachectic patients with advanced gastric and colorectal cancer

  • Original Articles
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

The serum levels of soluble tumor necrosis factor receptor I (sTNF-RI) were measured in 74 noncachectic patients including 42 with gastric cancer and 32 with colorectal cancer, as well as in 39 patients with severe cachexia and 15 healthy volunteers. The sTNF-RI levels increased with the advance of disease, being highest in the cachectic patients. The levels were inversely correlated with the serum concentrations of nutritional parameters such as prealbumin, transferrin, retinol binding protein, and the percentages of CD3(+) cells in the peripheral blood lymphocytes, and positively correlated with the serum concentration of immunosuppressive acidic protein (IAP) and soluble interleukin-2 receptors. These findings suggest that sTNF-RI could be an important prognostic factor to predict the advance of gastric and colorectal cancers and deterioration of the patient’s nutritional and immune activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lawson DH, Richmond A, Nixon DW, Rudman D (1982) Metabolic approaches to cancer cachexia. Annu Rev Nutr 2:277–301

    Article  PubMed  CAS  Google Scholar 

  2. Van Eys J (1985) Nutrition and cancer: physiological interrelationships. Annu Rev Nutr 5:435–461

    Article  PubMed  Google Scholar 

  3. Wesdorp RIC, Krause R, Von Meyenfeldt M (1983) Cancer cachexia and its nutritional implications. Br J Surg 70:352–355

    Article  PubMed  CAS  Google Scholar 

  4. Kern AK, Norton JA (1988) Cancer cachexia. J Parent Enteral Nutr 12:286–298

    Article  CAS  Google Scholar 

  5. Moldawer LL, Georgieff M, Lundholm K (1987) Interleukin 1, tumour necrosis factor-α (cachectin) and the pathogenesis of cancer cachexia. Clin Physiol 7:263–274

    Article  PubMed  CAS  Google Scholar 

  6. Oliff A (1988) The role of tumor necrosis factor (cachectin) in cachexia. Cell 54:141–142

    Article  PubMed  CAS  Google Scholar 

  7. Beutler B, Greenwalt D, Humes JD, Chang M, Pan Y-CE, Mathison J, Ulevitch R, Cerami A (1985) Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature 316:552–554

    Article  PubMed  CAS  Google Scholar 

  8. Cerami A, Ikeda Y, Le Trang N, Hotez PJ, Beutler B (1985) Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett 11:173–177

    Article  PubMed  CAS  Google Scholar 

  9. Tartaglia LA, Goeddel DV (1992) Two TNF receptors. Immunol Today 13:151–153

    Article  PubMed  CAS  Google Scholar 

  10. Engelmann H-P, Novick D, Wallach D (1990) Tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 265:1531–1536

    PubMed  CAS  Google Scholar 

  11. Engelmann H, Holtmann H, Brakebusch C, Avni YS, Sarov I, Naphar Y, Hadas E, Leitner O, Wallach D (1990) Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 265:14497–14504

    PubMed  CAS  Google Scholar 

  12. Nophar Y, Kemper O, Brakebusch C, Engelmann H, Zwang R, Aderka D, Holtmann H, Wallach D (1990) Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned suing amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 9:3269–3278

    PubMed  CAS  Google Scholar 

  13. Porteu F, Nathan C (1990) Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 172:599–607

    Article  PubMed  CAS  Google Scholar 

  14. Lantz M, Gullberg U, Nilsson E, Olsson I (1990) Characterization in vitro of a human tumor necrosis factor binding protein: a soluble form of a tumor necrosis factor receptor. J Clin Invest 86:1396–1402

    Article  PubMed  CAS  Google Scholar 

  15. Van Ostade X, Vandenabeele P, Everaerdt B, Loetscher H, Gentz R, Brockhaus M, Lesslauer W, Tavernier J, Brockaert P, Fiers W (1993) Human TNF mutants with selective activity on the p55 receptor. Nature 361:266–269

    Article  PubMed  Google Scholar 

  16. Hahn T, Toker L, Budilovsky S, Aderka D, Eshhar Z, Wallach D (1985) Use of a monoclonal antibody of a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein. Proc Natl Acad Sci USA 82:3814–3818

    Article  PubMed  CAS  Google Scholar 

  17. Nophar Y, Holtmann H, Ber R, Wallach D (1988) Dominance of resistance to the cytocidal effect of tumor necrosis factor in heterokaryons formed by fusion of resistant and sensitive cells. J Immunol 140:3456–3460

    PubMed  CAS  Google Scholar 

  18. Wallach D, Holtmann H, Engelmann H, Nophar Y (1988) Sensitization and desensitization to lethal effects of tumor necrosis factor and of interleukin-1. J Immunol 140:2994–2999

    PubMed  CAS  Google Scholar 

  19. Japanese Research Society for Cancer of the Stomach (1993) General rules for clinical and pathological studies on cancer of the stomach (12th edn.) Kanehara, Tokyo

    Google Scholar 

  20. Japanese Research Society for Cancer of the Colon and Rectum (1994) General rules for clinical and pathological studies on cancer of the colon, rectum and anus (5th edn.) Kanehara, Tokyo

    Google Scholar 

  21. Langkopf F, Atzpodien J (1994) Soluble tumour necrosis factor receptors as prognostic factors in cancer patients. Lancet 344:57–58

    Article  PubMed  CAS  Google Scholar 

  22. Aderka D, Engelmann H, Hornik V, Skornik Y, Levo Y, Wallach D, Kushtai G (1991) Increased serum levels of soluble forms for tumor necrosis factor in cancer patients. Cancer Res 51:5602–5607

    PubMed  CAS  Google Scholar 

  23. Brivio F, Lissoni P, Mancini D (1991) Effect of antitumor surgery on soluble interleukin-2 receptor serum levels. Am J Surg 161:466–469

    Article  PubMed  CAS  Google Scholar 

  24. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL (1985) Soluble interleukin 2 receptors are released by activated human lymphoid cells in vitro. J Immunol 135:3172–3176

    PubMed  CAS  Google Scholar 

  25. Rovelli F, Lissoni P, Crispino S (1988) Increased level of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study. Tumori 74:633–637

    PubMed  CAS  Google Scholar 

  26. Denz, H, Orth B, Weiss G, Herrmann R, Huber P, Wachter H Fuchs D (1993) Weight loss in patients with hematological neoplasias is associated with immune system stimulation. Clin Invest 71:37–41

    Article  CAS  Google Scholar 

  27. Olsson I, Lantz M, Nilsson E, Peetre C, Thysell H, Grubb A, Adolf G (1989) Isolation and characterization of a tumor necrosis binding protein from urine. Eur J Haematol 42:270–275

    Article  PubMed  CAS  Google Scholar 

  28. Rogy MA, Coyle SM, Oldenburg HSA, Rock CS, Barie PS, Van Zee KJ, Smith CG, Moldawer LL, Lowry SF (1994) Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Coll Surg 178:132–138

    PubMed  CAS  Google Scholar 

  29. Engelmann E, Aderka D, Rubinstein M, Rotmann D, Wallach D (1989) A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 264:11974–11980

    PubMed  CAS  Google Scholar 

  30. Seckinger P, Isaaz S, and Daye, J-M (1989) Purification and biologic characterization of a specific tumor necrosis factor inhibitor. J Biol Chem 264:11966–11973

    PubMed  CAS  Google Scholar 

  31. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF (1992) Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor á in vitro and in vivo. Proc Natl Acad Sci USA 89:4845–4849

    Article  PubMed  Google Scholar 

  32. Billiau A (1988) γ-interferon: the match that lights the fire? Immunol Today 9:37–40

    Article  PubMed  CAS  Google Scholar 

  33. Patton JS, Shepard HM, Wilking H, Lewis G, Aggarwal BB, Eessalu TE, Gavin LA, Grunfeld C (1986) Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells. Proc Natl Acad Sci USA 83:8313–8317

    Article  PubMed  CAS  Google Scholar 

  34. Langstein HN, Doherty GM, Fraker DL, Buresh GM, Norton JA (1991) The roles of ç-interferon and tumor necrosis factor á in an experimental rat model of cancer cachexia. Cancer Res 51: 2302–2306

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Nihon University School of Medicine, 30-1 Oyaguchi-kamimachi, Itabashi-ku, 173, Tokyo, Japan

    Masahiko Shibata, Motoo Takekawa & Sadao Amano

Authors
  1. Masahiko Shibata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Motoo Takekawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sadao Amano
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shibata, M., Takekawa, M. & Amano, S. Increased serum concentrations of soluble tumor necrosis factor receptor I in noncachectic and cachectic patients with advanced gastric and colorectal cancer. Surg Today 28, 884–888 (1998). https://doi.org/10.1007/s005950050247

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s005950050247

Key Words

Search

Navigation